Summary
Syndromes due to the abrupt withdrawal of drug treatment occur mainly with adrenal corticosteroids and agents with an action on either the cardiovascular system or central nervous system.
The abrupt withdrawal of antihypertensive therapy typically results in symptoms of overactivity in the sympathetic nervous system. Clonidine and β-adrenoceptor antagonists are clinically the most important of these agents, but numerous other drugs have been implicated. Overall, the problem is small when viewed in the context of the huge scale of prescribing of antihypertensive medicines. A more serious problem is the occurrence of crescendo angina following the abrupt withdrawal of β-adrenoceptor antagonists. Although other factors may be involved, adaptive up-regulation of β-adrenoceptor density is the most likely cause of crescendo angina, and renders the patient more susceptible to sympathetic nervous stimulation following withdrawal of treatment.
Besides leading to a recrudescence of the disease being treated, the withdrawal of corticosteroids can cause a variety of syndromes. In particular, problems can arise as a result of treatment-induced suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Another steroid withdrawal syndrome of unknown aetiology, without significant abnormalities of the HPA axis occurring, has been described. Benign intracranial hypertension may rarely follow steroid withdrawal in children.
The syndromes associated with withdrawal of drugs which have an action on the CNS are poorly understood. Withdrawal of neuroleptic drugs can be followed by symptoms that resemble those described following withdrawal of anticholinergic drugs, and those agents with the greatest muscarinic-receptor-blocking properties are those which are most frequently implicated. However, the less common withdrawal dyskinesias are thought to reflect up-regulation of dopaminergic receptors during long term treatment. Gastrointestinal symptoms predominate following the abrupt withdrawal of antidepressants but hypomania and an ‘akathisia-like’ syndrome have been reported. Barbiturates are no longer recommended as hypnotics because of severe effects of withdrawal and the existence of safer alternatives. Short acting barbiturates can be withdrawn by replacement with either phenobarbitone (phenobarbitol) or diazepam and subsequent gradual reduction in dose.
The recognition of dependency on benzodiazepines has been slow because of the similarity of mild withdrawal symptoms to the original problem which led to treatment being offered. Thus, long term benzodiazepine usage is common despite little evidence to support their long term efficacy in the treatment of mild affective disorders or insomnia. A reevaluation of their place in therapeutics is required. Substitution of long acting compounds is helpful prior to withdrawal. Sudden withdrawal of either benzodiazepines or barbiturates can also precipitate epilepsy in susceptible patients.
The problems of opioid withdrawal are well recognised. Various mechanisms are thought to be involved including up-regulation of adrenoceptors and functional deficiencies of endogenous opioid release. Traditionally, withdrawal has been managed by substitution with methadone.
Similar content being viewed by others
References
Aarons RD, Nies AS, Gal J, Hegstrand LR, Molinoff PB. Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. Journal of Clinical Investigation 65: 949–957, 1980
Alderman EL, Coltart DJ, Wettach GE, Harrison DC. Coronary artery syndromes after sudden propranolol withdrawal. Annals of Internal Medicine 81: 625–627, 1974
Amatruda Jr TT, Hollingsworth DR, D’Esopo ND, Upton GV, Bandy PK. A study of the mechanism of the steroid withdrawal syndrome: evidence for integrity of the hypothalamic-pituitary-adrenal system. Journal of Clinical Endocrinology and Metabolism 20: 339–354, 1960
Amatruda Jr TT, Hurst MM, D’Esopo ND. Certain endocrine and metabolic facets of the steroid withdrawal syndrome. Journal of Clinical Endocrinology and Metabolism 25: 1207–1217, 1965
Annegers JH, Hauser W, Elveback L. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20: 729–737, 1979
Ashton H. Benzodiazepine withdrawal: an unfinished story. British Medical Journal 288: 1135–1140, 1984
Axelrod L. Glucocorticoid therapy. Medicine 55: 39–65, 1976
Baastrup PC, Poulson JC, Schou M, Thomsen K, Amdisen A. Prophylactic lithium: double blind discontinuation in manic depressive and recurrent depressive disorders. Lancet 2: 326–330, 1970
Bailey RR, Neale TJ. Rapid withdrawal with blood pressure overshoot exaggerated by β-blockade. British Medical Journal 1: 942–943, 1976
Balter MB, Manheimer DI, Melinger GD, Uhlenhuth EH. A cross-national comparison of antianxiety/sedative drug use. Current Medical Research and Opinion 8 (Suppl. 4): 5–20, 1984
Beeley L. Adverse effects of drugs in later pregnancy. Clinics in Obstetrics and Gynaecology 13: 197–214, 1986
Bell NH. The glucocorticoid withdrawal syndrome. Advances in Experimental Medicine and Biology 171: 233–239, 1984
Bolli P, Buhler FR, Raeder EA, Amann F, Meier M, et al. Lack of β-adrenoceptor hypersensitivity after abrupt withdrawal of long term therapy with oxprenolol. Circulation 64: 1130–1134, 1981
Boomsma F, De Bruyn JHB, Derkx FHM, Schalekamp MAD. Opposite effects of captopril on angiotensin I converting enzyme ‘activity’ and ‘concentration’, relation between enzyme inhibition and long term blood pressure response. Clinical Science 60: 491–498, 1981
Branchey MH, Branchey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia. Psychopharmacology Bulletin 17: 118–119, 1981
Brown GM, Stancer HC, Moldofsky H. Withdrawal from long term high dose desipramine therapy: clinical and biological changes. Archives of General Psychiatry 25: 1261–1264, 1978
Burden AC, Alexander CPT. Rebound hypertension after acute methyldopa withdrawal. British Medical Journal 1: 1056, 1976
Byyny RL. Withdrawal from glucocorticoid therapy. New England Journal of Medicine 295: 30–32, 1976
Campbell BC, Elliott HL, Hamilton CA, Reid JL. Changes in blood pressure, heart rate and sympathetic activity on abrupt withdrawal of tiamenidine (Hoe 440) in essential hypertension. European Journal of Clinical Pharmacology 18: 449–545, 1980
Carter ME, James VHT. Effect of alternate day, single dose, corticosteroid therapy on pituitary-adrenal function. Annals of the Rheumatic Diseases 31: 379–383, 1972
Catalan J, Garth D, Edmonds G, Ennis J. The effects of non-prescription of anxiolytics in general practice I: controlled evaluation of psychiatric and social outcome. British Journal of Psychiatry 144: 593–602, 1984
Catalan J, Gath DH. Benzodiazepines in general practice: time for a decision. British Medical Journal 290: 1374–1376, 1985
Chadwick D. The discontinuation of antiepileptic therapy. In Pedley et al. (Eds) Recent advances in epilepsy 2, pp. 111–124, Churchill Livingstone, Edinburgh, 1985
Chamberlain P. Management of pituitary-adrenal suppression secondary to corticosteroid therapy. Paediatrics 67: 245–251, 1981
Charney DS, Heninger GR, Sternsberg DE, Landis H. Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. British Journal of Psychiatry 141: 377–386, 1982
Charney DS, Riordan CE, Kleber HD, Murburg M, Sternberg DE, et al. Clonidine and naltrexone. Archives of General Psychiatry 39: 1327–1332, 1982
Chouinard G, Bradwejn J, Annable L, Jones BD, Ross-Chouinard A. Withdrawal symptoms after long term treatment with low potency neuroleptics. Journal of Clinical Psychiatry 45: 500–502, 1984
Chouinard G, Jones BD. Neuroleptic induced supersensitivity psychosis: clinical and pharmacologic characteristics. American Journal of Psychiatry 137: 16–21, 1980
Chouinard G, Jones BD, Annable L. Neuroleptic-induced super-sensitivity psychosis. American Journal of Psychiatry 135: 1409–1410, 1978
Committee on Drugs. Neonatal drug withdrawal. Paediatrics 72: 895–902, 1983
Committee on the Review of Medicines. Recommendations on barbiturate preparations. British Medical Journal 2: 719–720, 1979
Committee on the Review of Medicines. Systematic review of the benzodiazepines. British Medical Journal 280: 910–917, 1980
Cope CL. The adrenal cortex in internal medicine. British Medical Journal 2: 847–853, 1966
Crane GE. Persistent dyskinesia. British Journal of Psychiatry 122: 395–405, 1973
Crane GE. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 27: 426–430, 1972
Cushman P, Dole VP. Detoxification of rehabilitated methadone maintained patients. Journal of the American Medical Association 226: 747–752, 1973
Danowski TS, Bonessi JV, Sabeh G, Sutton RD, Webster Jr MW, et al. Probabilities of pituitary adrenal responsiveness after steroid therapy. Annals of Internal Medicine 61: 11–26, 1964
de Bard ML. Diazepam withdrawal syndrome: a case of psychosis, seizure and coma. American Journal of Psychiatry 136: 104–105, 1979
Delgado-Escueta A, Treiman DM, Walsh GO. The treatable epilepsies. New England Journal of Medicine 308: 1508–1514 and 1576-1584, 1983
Dilsaver SC, Feinberg M, Greden JF. Antidepressant withdrawal symptoms treated with anticholinergic agents. American Journal of Psychiatry 140: 249–251, 1983
Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biological Psychiatry 19: 237–256, 1984
Dinon LR, Kum YS, Vander Veer JB. Clinical experience with chlorothiazide with particular emphasis on untoward response: a report of 121 case studies over a 15 month period. American Journal of Medicine Science 236: 533, 1958
Drury VMW. Benzodiazepines: a challenge to rational prescribing. Journal of the Royal College of General Practitioners 35: 86–88, 1985
Dunstan HP, Page IH, Tarazi RC, Frohlich ED. Arterial pressure responses to discontinuing antihypertensive drugs. Circulation 37: 370–379, 1968
Editorial. How to get patients off barbiturates. Drug and Therapeutics Bulletin 14, No. 2: 11–12, 1976
Editorial. Some problems with benzodiazepines. Drug and Therapeutics Bulletin 23, No. 6: 21–23, 1985
Emerson R, D’Sonza BJ, Vining EP, Holden KR, Mellitis ED, et al. Stopping medication in children with epilepsy: predictors of outcome. New England Journal of Medicine 304: 1125–1129, 1981
Fleischer N, Abe K, Liddle GW, Orth DN, Nicholson WE. ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression. Journal of Clinical Investigation 46: 196–204, 1967
Fontaine R, Chouinard G, Annabale L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. American Journal of Psychiatry 141: 848–852, 1984
Fraser HF, Isbell H, Eisenman AJ, Wilder A, Prescor FT. Chronic barbiturate intoxication: further studies. Archives of Internal Medicine 94: 34–41, 1954
Fraser HF, Shaver MR, Maxwell ES, Isbell H. Death due to withdrawal of barbiturates: report of a case. Annals of Internal Medicine 38: 1319–1325, 1953
Fraser HF, Wikler A, Essig CF, Isbell H. Degree of dependence induced by secobarbital or pentobarbital. Journal of the American Medical Association 166: 126–129, 1958
Frishman WH, Christodoulou J, Weksler B, Smithen C, Killip T, et al. Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance. American Heart Journal 95: 169–179, 1978
Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry 135: 1321–1324, 1978
Gaultiere CT, Staye J. Withdrawal symptoms after abrupt cessation of amitriptyline in an eight-year-old boy. American Journal of Psychiatry 136: 457–458, 1979
Gawin FH, Markoff RA. Panic anxiety after abrupt discontinuation of amitriptyline. American Journal of Psychiatry 138: 117–118, 1981
George CF, Nagle RE, Pentecost BL. Practolol in the treatment of angina pectoris: a double blind trial. British Medical Journal 1: 402–404, 1970
Geyskes GG, Boer P, Dorbout Mees EJ. Clonidine withdrawal: mechanism and frequency of rebound hypertension. British Journal of Clinical Pharmacology 7: 55–62, 1979
Gloag D. Epilepsy and employment. British Medical Journal 291: 2–3, 1985
Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate withdrawal symptoms. Lancet 2: 599–602, 1978
Goldberg AD, Raftery EB, Wilkinson PR. Blood pressure and heart rate and withdrawal of antihypertensive drugs. British Medical Journal 1: 1243–1246, 1977
Goldberg AD, Raftery EB, Wilkinson PR. The overshoot phenomenon on withdrawal of clonidine therapy. Postgraduate Medical Journal 52 (Suppl. 7): 128–134, 1976
Goldberg DP, Blackwell B. Psychiatric illness in general practice. British Medical Journal 2: 439–443, 1970
Goldstein RE, Corash LC, Tallman Jr JF, Lack CR, Hyde J, et al. Shortened platelet survival time and enhanced heart rate responses after abrupt withdrawal of propranolol from normal subjects. American Journal of Cardiology 47: 1115–1122, 1981
Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6,000 II: treatment and prognosis. British Medical Journal 287: 645–648, 1983
Graber AL, Ney RL, Nicholson WE, Island DP, Liddle GW. Natural history of pituitary-adrenal recovery following long term suppression with corticosteroids. Journal of Clinical Endocrinology and Metabolism 25: 11–16, 1965
Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalised chronic schizophrenic patients. American Journal of Psychiatry 123: 221–236, 1966
Haggit AC, Lader MH, Fonagy P. Regular review: clinical management of benzodiazepine dependence. British Medical Journal 291: 688–690, 1985
Hallstrom C. Benzodiazepines: clinical practice and central mechanisms. In Granville-Grossman (Ed) Recent advances in clinical psychiatry, Vol. 5, pp. 143–159, Churchill Livingstone, 1985
Hansson L. Clinical aspects of blood pressure crisis due to withdrawal of centrally acting antihypertensive drugs. British Journal of Clinical Pharmacology 15: 485s–489s, 1983
Hansson L, Hunyor SN, Julius S, Hoobler SW. Blood pressure crisis following withdrawal of clonidine with special reference to arterial and urinary catecholamine levels and suggestions for acute management. American Heart Journal 85: 605–610, 1973
Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. New England Journal of Medicine 269: 591–596, 1963
Hauger-Klevene JH. Treatment of clonidine rebound syndrome with sublingual captopril. New England Journal of Medicine 314(3): 181–182, 1986
Hershon HI, Kennedy PF, McGuire RJ. Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long term phenothiazine therapy. British Journal of Psychiatry 120: 41–50, 1972
Hodding GC, Jann M, Ackerman IP. Drug withdrawal syndromes: a literature review. Western Journal of Medicine 133: 383–391, 1980
Hokfelt B, Hedeland H, Dymling JF. Studies on catecholamines, renin and aldosterone following catepresan in hypertensive patients. European Journal of Pharmacology 10: 389–397, 1970
Hollister LE, Motzembeeker FP, Degan RO. Withdrawal reactions from chlordiazepoxide. Psychopharmacologia 2: 63–68, 1961
Holowach J, Thurston DL, O’Leary J. Prognosis in childhood epilepsy: follow up in 148 cases in which therapy had been suspended after prolonged anticonvulsant control. New England Journal of Medicine 286: 169–174, 1972
Hoobler SW, Kashima T. Central nervous system actions of clonidine in hypertension. Mayo Clinic Proceedings 52: 395–398, 1977
Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. American Heart Journal 102: 415–430, 1981
Howe JG. Lorazepam withdrawal seizures. British Medical Journal 280: 1163–1164, 1980
Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Annals of Internal Medicine 82: 613–618, 1975
Hurley DM, Vandongen R, Balin LJ. Failure of labetalol to prevent hypertensive crisis due to clonidine withdrawal. British Medical Journal 1: 1122, 1979
Isbell H. Abuse of barbiturates. Journal of the American Medical Association 162: 660–661, 1956
Isbell H, White WM. Clinical characteristics of addiction. American Journal of Medicine 14: 558–565, 1953
Isbell H, Wilder A, Eddy NB, Wilson JL, Moran CF. Tolerance of methadone. Journal of the American Medical Association 135: 888–894, 1947
Jackson G, Schwartz J, Kates RE, Harrison DC. Physiologic basis for beta blockade rebound: atenolol vs propranolol. Clinical Research 27 (abstract): 444, 1979
Jellinek T, Gardos E, Cole JO. Adverse effects of antiparkinson drug withdrawal. American Journal of Psychiatry 138: 1567–1571, 1981
Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. Drugs 18: 113–121, 1979
Juul-Jensen P. Frequency of recurrence after discontinuance of anticonvulsam therapy in patients with epileptic seizures: a new follow up study after 5 years. Epilepsia 9: 11–16, 1968
Kehlet H, Binder C. Value of an ACTH test in assessing hypothalamic-pituitary-adrenocortical function in glucocorticoid treated patients. British Medical Journal 2: 147–149, 1973.
Keim HJ, Drayer JIM, Case DB, Lopez-Ovejero J, Wallace JM, et al. A role for renin in rebound hypertension and encephalopathy after infusion of saralasin acetate. New England Journal of Medicine 295: 1175–1177, 1976
Kimball CP. Psychological dependence on steroids. Annals of Internal Medicine 75: 111–113, 1971
King JR, Hullin RP. Withdrawal symptoms from lithium: four case reports and a questionnaire study. British Journal of Psychiatry 143: 30–35, 1983
Kiyingi S, Shaw J. The phenomenon of β-adrenergic hypersensitivity following propranolol withdrawal studied in normal subjects. European Journal of Clinical Pharmacology 27: 423–428, 1984
Kleber HD, Riordan CE, Rounsville B, Kosten J, Charney D, et al. Clonidine in OP detoxification from methadone maintenance. Archives of General Psychiatry 42: 391–394, 1985
Klein HE, Broucek B, Greil W. Lithium withdrawal triggers psychotic states. British Journal of Psychiatry 139: 255–264, 1981
Kramer JC, Kleim DF, Fink M. Withdrawal symptoms following discontinuation of imipramine therapy. American Journal of Psychiatry 118: 549–550, 1961
Kristensen B, Steiness E, Weeke J. Propranolol withdrawal and thyroid hormones in patients with essential hypertension. Clinical Pharmacology and Therapeutics 23: 624–629, 1978
Lacoursiere RB, Spohn HE, Thompson K. Medical effects of abrupt neuroleptic withdrawal. Comprehensive Psychiatry 17: 285–294, 1976
Lapierre YD, Gagnan A, Kokkinidis L. Rapid recurrence of mania following lithium withdrawal. Biological Psychiatry 15: 859–864, 1980
Law III W, Petti JA, Kazdin AE. Withdrawal symptoms after graduated cessation of imipramine in children. American Journal of Psychiatry 138: 647–650, 1981
Lawrence JM. Reactions to withdrawal of antidepressants, anti-parkinsonian drugs and lithium. Psychosomatics 26: 869–877, 1985
Lesser I. Case report of withdrawal dyskinesia associated with amoxapine. American Journal of Psychiatry 140: 1358–1359, 1983
Liddle GW. The adrenal cortex. In Williams (Ed.). Textbook of endocrinology, 5th ed., p. 233, Saunders Company, Philadelphia, 1974
Lindenfeld J, Crawford MH, O’Rourke RA, Levine SP, Montiel MM, et al. Adrenergic responsiveness after abrupt propranolol withdrawal in normal subjects and in patients with angina pectoris. Circulation 62: 704–711, 1980
Livanou T, Ferriman D, James VHT. Recovery of hypothalamic-pituitary-adrenal function after corticosteroid therapy. Lancet 2: 856–857, 1967
Maberly DJ, Gibson GJ, Butler AG. Recovery of adrenal function after substitution of beclomethasone dipropionate for oral steroids. British Medical Journal 1: 778–782, 1973
MacGregor GA, Tasker PRW, de Wardener HE. Diuretic-induced oedema. Lancet 1: 489–492, 1975
Mackinnon GL, Parker WA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. American Journal of Drug and Alcohol Abuse 9: 19–33, 1982
Madhok R, Zoma A, Capell H. Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin. British Medical Journal 291: 249–250, 1985
Mannaioni PF. Clinical pharmacology of drug dependence — English edition, pp. 15–78, Piccin Nuovalibrarra, 1984
Margo A, McMahon P. Lithium withdrawal triggers psychosis. British Journal of Psychiatry 141: 407–410, 1982
Martin WR, Jasinski DR. Physiological parameters of morphine dependence in man: tolerance, early abstinence, protracted abstinence. Journal of Psychiatric Research 1: 9–17, 1969
Maslowski AH, Nicholls MG, Ikram H, Espiner EA, Turner JG. Haemodynamic, hormonal and electrolyte responses to withdrawal of long term captopril treatment for heart failure. Lancet 2: 959–961, 1981
McCawley A. Cortisone habituation: a clinical note. New England Journal of Medicine 273: 976, 1965
Merritt H. Medical treatment in epilepsy. British Medical Journal 1: 666–669, 1958
Miller RR, Olsen HG, Amsterdam EA, Mason DJ. Propranolol withdrawal rebound phenomenon: exacerbation of coronary events after abrupt cessation of anti-anginal therapy. New England Journal of Medicine 293: 416–418, 1975
Mirin SM, Schatzberg AF, Creasey DE. Hypomania and mania after withdrawal of tricyclic antidepressants. American Journal of Psychiatry 131: 87–89, 1981
Murphy SM, Owen RT, Tyrer PJ. Withdrawal symptoms after 6 weeks treatment with diazepam. Lancet 2: 1389, 1984
Myers MG, Freeman MR, Juma ZA, Wirenberg G. Propranolol withdrawal in angina pectoris: a prospective study. American Heart Journal 97: 298–302, 1979
Nichols T, Nugent CA, Tyler FH. Diurnal variation in suppression of adrenal function by glucocorticoids. Journal of Clinical Endocrinology and Metabolism 25: 343–349, 1965
O’Brien ET, McKinnon I. Propranolol withdrawal in hypertension: propranolol and polythiazide in the treatment of hypertension. British Heart Journal 34: 1042–1044, 1972
Olajide D, Lader M. Depression following withdrawal from long term benzodiazepine use: a report of 4 cases. Psychological Medicine 14: 937–940, 1984
Olsson G, Hjemdahl P, Rehnqvist N. Rebound phenomena following gradual withdrawal of chronic metoprolol treatment in patients with ischaemic heart disease. American Heart Journal 108: 454–462, 1984
Owen F, Cross AJ, Crow TJ. Increased dopamine receptor sensitivity in schizophrenia. Lancet 2: 223–226, 1978
Owen RT, Tyrer P. Benzodiazepine dependence: a review of the evidence. Drugs 25: 385–398, 1983
Packer M, Meller J, Medina N, Gorlin R, Hereman MV. Rebound haemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. New England Journal of Medicine 301: 1193–1197, 1979
Pederson OL. Comparison of metoprolol and hydrochlorothiazide as antihypertensive agents. European Journal of Clinical Pharmacology 10: 381–384, 1976
Pederson OL, Mikkelsen E, Nielsen JL, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension: effect on blood pressure, heart rate and plasma catecholamines and prolactin. European Journal of Clinical Pharmacology 15: 215–217, 1979
Petti TA, Law III W. Abrupt cessation of high dose imipramine treatment in children. Journal of the American Medical Association 246: 768–769, 1981
Petursson H, Lader MH. Withdrawal from long term benzodiazepine treatment. British Medical Journal 283: 643–645, 1981
Pevnick JS, Jasinski DR, Haertzen CA. Abrupt withdrawal from therapeutically administered diazepam. Archives of General Psychiatry 35: 995–998, 1978
Pitt B. Withdrawal symptoms after stopping phenelzine? British Medical Journal 2: 332–333, 1974
Preskhorn SH, Denner LJ. Benzodiazepines and withdrawal psychosis. Journal of the American Medical Association 237: 36–38, 1977
Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. International Journal of the Addictions 20: 845–867, 1985
Raftery EB. Cardiovascular drug withdrawal syndromes: a potential problem with calcium antagonists. Drugs 28: 371–374, 1984
Ram CVS, Holland OB, Fairchild C, Gomez-Sanchez CE. Withdrawal syndrome following cessation of guanabenz therapy. Journal of Clinical Pharmacology 19: 148–150, 1979
Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. British Journal of Clinical Pharmacology 13 (Suppl. 2): 345s–351s, 1982
Rangno RE, Langlois S, Lutterodt A. Metoprolol withdrawal phenomena: mechanism and prevention. Clinical Pharmacology and Therapeutics 31: 8–15, 1982a
Rangno RE, Nattel S, Lutterodt A. Prevention of propranolol withdrawal mechanism. American Journal of Cardiology 49: 828–833, 1982b
Redmond Jr DE, Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. Annual Review of Neuroscience 7: 443–478, 1984
Reid JL. The clinical pharmacology of clonidine and related central antihypertensive agents. British Journal of Clinical Pharmacology 12: 295–302, 1981
Reid JL, Campbell BC, Hamilton CA. Withdrawal reaction following cessation of central a-adrenergic receptor agonists. Hypertension 6: 71–75, 1984
Reid JL, Wing LMH, Dargrett J, Davies DS, Hamilton CA, et al. Clonidine withdrawal in hypertension. Lancet 1: 1171–1174, 1977
Report of the Medical Working Group on Drug Dependence: guidelines of good clinical practice in the treatment of drug misuse, p. 20, DHHS, London, 1984
Reynolds EH. Chronic antiepileptic toxicity: a review. Epilepsia 16: 319–352, 1975
Rosenthal T, Rabinowitz B, Boichis H, Elazar E, Brauner A, et al. Use of labetalol in hypertensive patients during discontinuation of clonidine therapy. European Journal of Clinical Pharmacology 20: 237–240, 1981
Ross PJ, Jones MK, John R. Thyroid hormone levels after propranolol withdrawal. Clinical Science 58: 22P, 1980
Rowan AJ, Scott DT. Major status epilepticus. Acta Neurologica Scandinavica 46: 573–584, 1976
Salassa RM, Bennett WA, Keating Jr FR, Sprague RG. Postoperative adrenal cortical insufficiency: occurrence in patients previously treated with cortisone. Journal of the American Medical Association 152: 1509, 1953
Santos AB, McCurdy L. Delirium after abrupt withdrawal from doxepin: case report. American Journal of Psychiatry 137: 239–240, 1980
Sathananthan GL, Gershon S. Imipramine withdrawal: an akathisia-like syndrome. American Journal of Psychiatry 130: 1286–1287, 1973
Schrumpf JD, Sheps DS, Wolfson S, Aronson AC, Cohen L. Altered haemoglobin-oxygen affinity with long-term propranolol therapy in patients with coronary artery disease. American Journal of Cardiology 40: 76–82, 1977
Schweigert BF. Neonatal barbiturate withdrawal. Journal of the American Medical Association 221: 1282, 1972
Scott JN, McDevitt DG. Rebound hypertension after acute methyldopa withdrawal. British Medical Journal 2: 367, 1976
Shinnar S, Vining EPG, Mellitus D, D’Souza BJ, Holden K, et al. Discontinuing antiepileptic medication in children with epilepsy after 2 years without seizures: a prospective study. New England Journal of Medicine 313: 976–986, 1985
Shiroff RA, Mathis J, Zelis R, Schneck D, Babb J, et al. Propranolol rebound: a retrospective study. American Journal of Cardiology 41: 778–780, 1978
Small JG, Small IF, Moore DF. Experimental withdrawal of lithium in recovered manic depressive patients: a report of 5 cases. American Journal of Psychiatry 127: 131–134, 1971
Spiegel RJ, Oliff AI, Bruton J, Vigersky RA, Echelberger CK, et al. Adrenal suppression after short term corticosteroid therapy. Lancet 1: 630–633, 1979
Stern SL, Mendels J. Withdrawal symptoms during the course of imipramine therapy. Journal of Clinical Psychiatry 41: 66–67, 1980
Stewart RB, Cluff LE. A review of medication errors and compliance in ambulant patients. Clinical Pharmacology and Therapeutics 13: 463–468, 1972
Strauss FD, Franklin SS, Lewin AJ, Maxwell MH. Withdrawal of antihypertensive therapy: hypertensive crisis in renovascular hypertension. Journal of the American Medical Association 238: 1734–1736, 1977
Streck F, Lockwood DH. Pituitary adrenal recovery following short term suppression with corticosteroids. American Journal of Medicine 66: 910–914, 1979
Tyrer PJ. Benzodiazepines on trial. British Medical Journal 288: 1101–1102, 1984
Tyrer PJ, Owen R, Dawking S. Gradual withdrawal of diazepam after long term therapy. Lancet 1: 1402–1406, 1983
Tyrer PJ, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1: 520–522, 1981
Tyrer PJ, Seivewright N. Identification and management of benzodiazepine dependence. Postgraduate Medical Journal 60 (Suppl. 2): 41–46, 1984
Vanholder R, Carpentier J, Schurgers M, Clement DL. Rebound phenomenon during gradual withdrawal of clonidine. British Medical Journal 1: 1138, 1977
Walker AE, Adamkiewicz JJ. Pseudotumor cerebri associated with prolonged corticosteroid therapy. Journal of the American Medical Association 188: 779–784, 1964
Watkins L, Russel RP, Walker WG. Propranolol withdrawal in the pathogenesis of hypertension following coronary artery bypass surgery. Proceedings of the International Society of Hypertension, Paris, p. 295, 1978
Weber MA. Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. Journal of Cardiovascular Pharmacology 2 (Suppl. 1): S73–S89, 1980
Whitsett TL. Abrupt cessation of treatment with centrally acting antihypertensive agents: a review. Chest (2 Suppl.): 400-402, 1983
Whitsett TL, Chrysant SG, Dilland BL, Anton AG. Abrupt cessation of clonidine administration: a prospective study. American Journal of Cardiology 41: 1285–1296, 1978
Wilder A. Diagnosis and treatment of drug dependence of the barbiturate type. American Journal of Psychiatry 125: 758–765, 1968
Wilkinson DG. Difficulty in stopping lithium prophylaxis. British Medical Journal 1: 235–236, 1979
Wilson DF, Wilson OF, Peel JS, Turner AS. Trasicor in angina pectoris: a double blind trial. British Medical Journal 2: 155–157, 1969
Winokur A, Rickets K, Greenblatt DJ, Snyder PJ, Schatz NJ. Withdrawal reaction from long term low dosage administration of diazepam: a double blind placebo controlled case study. Archives of General Psychiatry 37: 101–105, 1980
Witschky JK, Malone GL, Holden DL. Psychosis after neuroleptic withdrawal in a manic depressive patient. American Journal of Psychiatry 141: 105–106, 1984
Yahr MD, Sciarra D, Carter S, Merritt H. Evaluation of standard anticonvulsant therapy in 319 patients. Journal of the American Medical Association 150: 663–667, 1952
Zamboulis C, Reid JL. Withdrawal of guanfacine after long term treatment in essential hypertension. European Journal of Clinical Pharmacology 19: 19–24, 1981
Zelson C. Infant of the addicted mother. New England Journal of Medicine 288: 1393–1395, 1973
Zsoter TT, Beanlands DS. Propranolol in angina pectoris. Archives of Internal Medicine 124: 584–587, 1969
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
George, C.F., Robertson, D. Clinical Consequences of Abrupt Drug Withdrawal. Med Toxicol Adverse Drug Exp 2, 367–382 (1987). https://doi.org/10.1007/BF03259954
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259954